

Sentinels of Immunity: The Role of Dendritic Cells in Antigen Presentation

Dr. Priya Reddy,

Associate Professor,

Department of Immunology,

National Institute of Biomedical Sciences, Hyderabad, India

Email: priya.reddy@nibs.edu.in

Aditya Sharma,

Research Scholar,

Department of Microbiology,

Advanced Life Sciences Institute, Pune, India

Email: aditya.sharma@alsi.ac.in

Abstract

Dendritic cells (DCs) are pivotal antigen-presenting cells that bridge innate and adaptive immunity by capturing, processing, and presenting antigens to T cells. This paper reviews the biology of dendritic cells, focusing on their subsets, maturation processes, and mechanisms of antigen uptake and presentation through MHC class I and II pathways. We discuss cross-presentation, cytokine secretion, and costimulatory molecule expression, which determine the quality and magnitude of T-cell responses. A table summarizing dendritic cell subsets and their primary functions is included. Understanding DC-mediated antigen presentation provides insights into vaccine development, immunotherapy, and modulation of immune responses in infections, cancer, and autoimmune diseases.

Keywords: *Dendritic cells, antigen presentation, MHC class I, MHC class II, cross-presentation, immune response, T cells*

INTRODUCTION

Dendritic cells (DCs) are specialized antigen-presenting cells critical for initiating adaptive immune responses. First described by Ralph Steinman in the 1970s, DCs act as sentinels of the immune system, detecting pathogens and translating this information to naïve T cells. DCs are widely distributed in peripheral tissues, including skin, mucosa, and lymphoid organs. Upon encountering antigens, DCs undergo maturation, characterized by upregulation of MHC molecules and costimulatory molecules such as CD80, CD86, and CD40, facilitating T-cell activation. The ability of DCs to present antigens through both MHC class I and II pathways makes them indispensable for orchestrating cellular and humoral immune responses.*

DENDRITIC CELL SUBSETS AND CHARACTERISTICS

DCs can be classified based on origin, surface markers, and functional properties:

Conventional Dendritic Cells (cDCs)

- Found in lymphoid and non-lymphoid tissues
- Efficient at antigen uptake and presentation to CD4+ and CD8+ T cells
- Subdivided into cDC1 and cDC2: cDC1 specialize in cross-presentation to CD8+ T cells, while cDC2 mainly activate CD4+ T helper cells

Plasmacytoid Dendritic Cells (pDCs)

- Predominantly secrete type I interferons in response to viral infections
- Express TLR7 and TLR9 for viral RNA/DNA detection
- Play a role in antiviral immunity and immune tolerance

Monocyte-derived Dendritic Cells (moDCs)

- Differentiate from monocytes during inflammation
- Contribute to local antigen presentation and cytokine secretion
- Bridge innate immune responses with adaptive immunity during infection

Table 1: Dendritic Cell Subsets and Their Functions

DC Subset	Primary Location	Main Function
cDC1	Lymphoid & non-lymphoid	Cross-presentation, activation of CD8+ T cells

	tissues	
cDC2	Peripheral tissues	Activation of CD4+ T helper cells, cytokine production
pDC	Blood, lymphoid organs	Type I interferon production, antiviral defense
moDC	Inflammatory sites	Antigen presentation, cytokine secretion, inflammation

Table 1 summarizes major DC subsets and their functional roles in immune responses.

ANTIGEN UPTAKE AND PROCESSING

DCs utilize multiple mechanisms to capture antigens, including:

- **Phagocytosis:** Engulfment of pathogens or apoptotic cells
- **Endocytosis:** Receptor-mediated uptake of soluble antigens
- **Macropinocytosis:** Non-specific uptake of extracellular fluid and antigens

Once internalized, antigens are processed in endosomal or cytosolic compartments. Peptides derived from intracellular antigens are loaded onto **MHC class I molecules**, whereas extracellular antigens are processed for **MHC class II presentation**. DCs also perform **cross-presentation**, enabling exogenous antigens to be presented on MHC class I to CD8+ T cells, critical for antiviral and antitumor responses.

MATURATION AND SIGNALING

Immature DCs efficiently capture antigens but exhibit low T-cell stimulatory capacity. Upon encountering PAMPs via pattern recognition receptors (TLRs, NOD-like receptors), DCs undergo maturation characterized by:

- Upregulation of **MHC I & II molecules**
- Increased expression of **costimulatory molecules** (CD80, CD86, CD40)
- Secretion of cytokines such as **IL-12, IL-6, and TNF- α**
- Migration to lymphoid organs via **CCR7 signaling**

Mature DCs efficiently present antigens to T cells, shaping the magnitude and quality of adaptive immune responses.

CROSS-PRESENTATION AND T-CELL ACTIVATION

Cross-presentation enables DCs to present extracellular antigens on MHC class I molecules to activate CD8⁺ cytotoxic T lymphocytes. This mechanism is essential for antiviral immunity, tumor surveillance, and vaccination. DCs also secrete cytokines that influence T-cell differentiation: IL-12 promotes Th1 responses, IL-6 and IL-23 support Th17 differentiation, and IL-10 modulates regulatory T cells.

The balance between costimulatory and inhibitory signals provided by DCs determines the outcome of T-cell activation, tolerance, or anergy, influencing immune homeostasis.

CLINICAL IMPLICATIONS

DCs are central to vaccine efficacy, immunotherapy, and infectious disease control:

- **Vaccines:** DC-targeted vaccines enhance antigen-specific T-cell responses, improving immunity against infectious diseases and cancer.
- **Cancer Immunotherapy:** Ex vivo-generated DCs loaded with tumor antigens stimulate cytotoxic T-cell responses and improve antitumor immunity.
- **Autoimmunity:** Dysregulated DC activation contributes to autoimmune pathogenesis by presenting self-antigens in an immunogenic context.
- **Infection:** DC dysfunction can impair antiviral responses, facilitating chronic infections or pathogen persistence.

Understanding DC biology informs therapeutic strategies for modulating immune responses in health and disease.

FUTURE DIRECTIONS

Emerging research focuses on:

- **DC-based personalized vaccines:** Enhancing immunogenicity through patient-specific antigen presentation
- **Modulating DC signaling:** Targeting TLRs, NOD-like receptors, and costimulatory pathways to optimize immune responses
- **Systems immunology approaches:** Mapping DC-T cell interactions using multi-omics and single-cell analysis
- **Nanoparticle-mediated antigen delivery:** Improving DC targeting and cross-presentation efficiency

These strategies aim to harness the full potential of DCs in immunotherapy, vaccination, and infectious disease control.

CONCLUSION

Dendritic cells are essential mediators of immune responses, bridging innate and adaptive immunity through efficient antigen capture, processing, and presentation. Their ability to present antigens via MHC class I and II pathways, perform cross-presentation, and secrete cytokines makes them central to T-cell activation and immune regulation. Understanding the biology, maturation, and functional specialization of DC subsets informs vaccine development, immunotherapy, and modulation of immune responses in infections, cancer, and autoimmune diseases. Targeted manipulation of DC function offers promising avenues for enhancing protective immunity and controlling pathological immune responses.

REFERENCES

1. Banchereau, J., & Steinman, R. M. (1998). Dendritic cells and the control of immunity. *Nature*, 392, 245–252.
2. Steinman, R. M., & Cohn, Z. A. (1973). Identification of a novel cell type in peripheral lymphoid organs of mice. *Journal of Experimental Medicine*, 137(5), 1142–1162.
3. Guermonprez, P., et al. (2002). Antigen presentation and T cell stimulation by dendritic cells. *Annual Review of Immunology*, 20, 621–667.
4. Heath, W. R., & Carbone, F. R. (2001). Cross-presentation in viral immunity and self-tolerance. *Nature Reviews Immunology*, 1, 126–134.
5. Reis e Sousa, C. (2006). Dendritic cells in a mature age. *Nature Reviews Immunology*, 6, 476–483.
6. Palucka, K., & Banchereau, J. (2012). Cancer immunotherapy via dendritic cells. *Nature Reviews Cancer*, 12, 265–277.
7. Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013). The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. *Annual Review of Immunology*, 31, 563–604.
8. Collin, M., & Bigley, V. (2018). Human dendritic cell subsets: An update. *Immunology*, 154, 3–20.